Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation

Linghuan Li,1 Wanfang Zheng,1 Can Wang,1 Jiameng Qi,1 and Hanbing Li1,2

1Institute of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, China
2Section of Endocrinology, School of Medicine, Yale University, New Haven 06520, USA

CorrespondenceshouldbeaddressedtoHanbingLi;hanbiballee@zjut.edu.cn

Received 21 January 2020; Accepted 13 April 2020; Published 30 April 2020

AcademicEditor:SakthivelMuniyan

Previous studies presented various beneficial effects of mogrosides extract from Siraitia grosvenorii, which has been included in the list of Medicine Food Homology Species in China. Mogroside V (MV) is one of the main ingredients in mogrosides extract; however, whether and how MV improves impaired lipid metabolism in the liver remains to be elucidated. Herein, we investigated the therapeuticeffects of mogroside V upon hepatic steatosis in vivo and in vitro and explored the underlying mechanisms. The results showed that MV significantly ameliorated hepatic steatosis in high-fat diet- (HFD-) fed mice. Furthermore, the increased protein expression of PPAR-γ, SREBP-1, and FASN and mRNA expression of pparg, srebp1, scd1, and fasn in the liver in HFD-fed mice, which contribute to de novo lipogenesis, were dose-dependently reversed by MV treatment. Meanwhile, MV counteracted the suppressed expression of PPAR-α and CPT-1A and mRNA expression of atgl, hasl, ppara, and cplta, thus increasing lipolysis and fatty acid oxidation. In addition, in free fatty acids- (FFAs-) incubated LO2 cells MV downregulated de novo lipogenesis and upregulated lipolysis and fatty acid oxidation, thereby attenuating lipid accumulation, which was significantly abrogated by treatment with Compound C, an inhibitor of AMP-activated protein kinase (AMPK). Taken together, these results suggested that MV exerted a pronounced effect upon improving hepatic steatosis through regulating the disequilibrium of lipid metabolism in the liver via an AMPK-dependent pathway, providing a potential lead compound candidate for preventing nonalcoholic fatty liver disease.

1. Introduction

Over the past several decades, infectious liver diseases have been restrained effectively by excellent policies and novel therapeutic approaches. While noninfectious chronic liver disease is still a huge public threat to human health, one of the most common forms of chronic liver disease is nonalcoholic fatty liver disease (NAFLD). NAFLD is referred to as a continuum of liver conditions, ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis to cirrhosis [1]. And obesity is one of the most important clinical factors strongly correlated with NAFLD due to overnutrition and lack of physical activity. In obese individuals, excessive plasmic nonesterified fatty acids are primarily delivered by dietary and adipose tissue lipolysis of triglycerides, a process that is regulated by insulin action and dysregulated under circumstances of insulin resistance, and thus pose a great challenge to the liver. When fatty acids are either overwhelmingly supplied or improperly disposed, they may lead to the accumulation of toxic lipid species that provoke further hepatocellular injury. In 2018, up to 25 percent of the world population is involved in NAFLD [2]. So far, the prevention and treatment of NAFLD have become a hot topic in the field of future therapeutic regimens, research, and development.

The hallmark of NAFLD, hepatic lipid accumulation, results from increased de novo lipogenesis in the liver and decreased fatty acid β-oxidation. FASN is a key enzyme in the de novo lipogenesis pathway that is responsible for the synthesis of excess fat in the liver of patients with NAFLD.
and regulated by SREBP-1 and PPAR-γ. CPT-1A is essential for fatty acid oxidation, a process that metabolizes fats and converts them into energy, which is regulated by a transcriptional factor PPAR-α [3]. The understanding of the pathophysiology of NAFLD/NASH has evoked the proposition of the multihit model including adipose tissue dysfunction causing the release of excess FFAs from the adipocytes, increased levels of inflammatory mediators promoting insulin resistance, lipotoxicity, oxidative stress, and endoplasmic reticulum stress, and depletion of the synthesis, and hepatic levels of polyunsaturated fatty acids (PUFA) as well [4, 5].

Mogrosides belong to cucurbitane-type glycosides, which are the major bioactive constituents derived from *Siraitia grosvenorii* fructus. The fruit of *Siraitia grosvenorii* has been traditionally used in the treatment of lung congestion, dry cough, sore throat, and constipation for thousands of years in China [6]. And mogrosides from *Siraitia grosvenorii* fruits possess several advantageous properties including low calories, low toxicity, and high sweetness, which are approximately 300 times sweeter than those of sucrose. Furthermore, emerging literature has elucidated that mogrosides display multiple pharmacological effects on cancer, oxidative stress, fibrosis, inflammation, allergic asthma, obesity, and diabetes [6–10]. Liu et al. have shown that mogroside-rich extract performs a pronounced lipid-lowering effect in plasma and liver from high-fat diet (HFD)/streptozotocin-induced diabetic mice [11]. Meanwhile, it has been reported that mogrosides can inhibit the progress of NAFLD in HFD-fed mice [12]. Mogroside V is one of the main components in the mogroside-rich extract from *Siraitia grosvenorii* fructus. However, whether mogroside V affects NAFLD has not yet been investigated, and the in-depth mechanism needs to be elucidated.

In this study, we investigated the effects of mogroside V upon hepatic steatosis in mice fed a high-fat diet (HFD) and LO2 cells treated with free fatty acids (FFAs) and further explored the molecular mechanisms contributing to the beneficial effects, providing experimental evidence for developing new drug candidates against NAFLD.

2. Materials and Methods

2.1. Chemicals and Reagents. Mogroside V (MV, HPLC > 98%, Figure S1) was obtained from Nanjing Plant Origin Biological Technology Co., Ltd. (Nanjing, China; CA:88901-36-4). Dorosomorphin (Compound C) was supplied by MedChemExpress (purity: 99.65%, Jersey, USA; CA: 866405-64-3). Palmitic acid, oleic acid, and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were provided by Sigma (St. Louis, MO, USA). Triglyceride (TG), nonesterified fatty acid (NEFA), total cholesterol (T-CHO), aspartate aminotransferase (AST), and alanine transaminase (ALT) assay kits were obtained from Jiancheng Bioengineering Institute (Nanjing, China). Insulin ELISA kit was from Shanghai Hengyuan Biological Technology Co., Ltd (Shanghai, China). AMPK and p-AMPK (phospho-Thr172) antibodies were purchased from Santa Cruz (Dallas, USA); PPAR-γ, PPAR-α, FASN, CPT-1A, and α-tubulin antibodies were supplied by Proteintech (Chicago, USA); SREBP-1 antibody was purchased from Novus Biologicals (Littleton, Colorado, USA). TRizol reagent was purchased from Invitrogen (Carlsbad, USA); BeyoRT™ III cDNA Synthesis Kit and BeyoFast™ SYBR Green qPCR Mix were purchased from Beyotime Institute of Biotechnology (Jiangsu, China).

2.2. Animal Experimental Design. Male C57BL/6 mice were purchased from the Center of Experimental Animals of East China Normal University (Shanghai, China; license no. SCXK 2016-0004). All mice were acclimated to the laboratory for a week before the follow-up experiments and were randomly assigned to two groups: the control group (n = 9) was fed a standard chow diet (Zhejiang Academy of Medical Sciences, Hangzhou, China) for 18 weeks and received a daily oral gavage of sterile saline for the last 8 weeks, and HFD group (n = 36) was fed high-fat diet (Table S1 [13]) for 10 weeks and had more than 20% weight gain. And then the HFD group was randomly divided into four subgroups: HFD group, low-dose MV group, medium-dose MV group, and high-dose MV group; all groups continued to be fed high-fat diets with corresponding treatments for 8 weeks. The HFD group received a daily oral gavage of sterile saline; the low-dose MV, medium-dose MV, and high-dose MV group were orally administered with different dosages of MV (25, 50, and 100 mg/kg/day), respectively. Before sacrificed, all animals fasted and minim blood was collected from the tail vein to measure blood glucose concentration using One-touch Ultraceaasy (Johnson, New Jersey, USA). Blood was collected from the fundus venous plexus for biochemical analysis. All mice livers were instantly removed and weighed. Pieces of the livers were fixed in 4% paraformaldehyde solution for pathological analysis. And the remaining liver samples were collected, snap-frozen in liquid nitrogen, and stored at −80°C for further study. The procedures of animal experiments were approved by the Institutional Animal Care and Use Committee at Zhejiang University of Technology Laboratory Animal Center (SYXK (Zhe)2017-0001) and were in compliance with the Guide for the Care and Use of Laboratory Animal published by the National Academy Press (Washington, DC, 1996).

2.3. Serum Biochemical Analysis. Blood samples were centrifuged at 4,000 g for 5 min to obtain serum. Serum NEFA, TG, T-CHO, AST, and ALT levels were determined by assay kits according to the manufacturer’s instructions. The level of insulin was measured using an insulin ELISA kit following the manufacturer’s protocol. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: fasting insulin concentration (mIU/ml) × fasting glucose level (mmol/L)/22.5.

2.4. Cell Culture and Treatment. The human LO2 (HL-7702) cell line was acquired from Procell Life Science & Technology Co., Ltd. (Wuhan, China). LO2 cells were cultured in
2.5. Cell Viability Assay. Cell viability was assessed using the MTT assay. The cells were seeded (4 × 10³ cells/well) in a 96-well cell culture plate, incubated for 8 h, and then treated with different concentrations of MV (15, 30, 60, and 120 μM) for 24 h. The MTT was dissolved at 5 mg/mL in phosphate-buffered saline. After incubation, the medium was replaced with 200 μL fresh medium and each well was added with 20 μL of MTT solution. After 4 h, the solution was discarded, and dimethyl sulfoxide was added to dissolve the formazan crystal. Finally, the absorbance was measured at 490 nm on an ELISA plate reader (BioTek SynergyH1, Winooski, USA).

2.6. Histopathological Analysis. After fixation, liver specimens were embedded in paraffin and sliced into sections. Then, these sections were stained with hematoxylin-eosin (H&E) for histological examination. For Oil Red O staining, after fixation, the tissues were embedded in the optimum cutting temperature compound and stored at −80°C for 24 h. The MTT was dissolved at 5 mg/mL in phosphate-buffered saline. After incubation, the medium was replaced with 200 μL fresh medium and each well was added with 20 μL of MTT solution. After 4 h, the solution was discarded, and dimethyl sulfoxide was added to dissolve the formazan crystal. Finally, the absorbance was measured at 490 nm on an ELISA plate reader (BioTek SynergyH1, Winooski, USA).

2.7. Immunoblotting. Proteins of the liver or cells were extracted by radio immunoprecipitation assay lysis buffer containing protease inhibitor and phosphatase inhibitor. Protein samples were separated on 8% SDS-PAGE and transferred to PVDF membranes. Then, the membranes were blocked with 5% BSA solution for 2 h at room temperature. After blocking, the membranes were exposed to primary antibodies overnight at 4°C, washed with TBST, and incubated with appropriate secondary antibodies for 2 h at room temperature. Subsequently, the membranes were visualized by enhanced chemiluminescence method, and the intensity of the band was determined using ImageJ software.

2.8. Total RNA Extraction and Quantitative PCR. Total RNA was extracted from livers using TRlzol reagent. One microgram of total RNA was converted to cDNA using the BeyoRT™ III cDNA Synthesis Kit according to the manufacturer’s instructions. The cDNA products were performed with SYBR Green qPCR Mix and corresponding primers (Sangong Biotech, Shanghai, China) on StepOne™ Real-Time PCR System (Applied Biosystems). Relative gene expression was normalized by the housekeeping endogenous gene gapdh and fold changes were calculated using the 2−ΔΔCt method. The sequences of primers are listed in Table 1.

2.9. Statistical Analysis. All values are expressed as the mean ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) with Tukey’s post hoc test was adopted to evaluate the statistical significance of the difference between multiple groups, and t-test was used to assess the difference between two groups by GraphPad Prism 5. *p < 0.05 was regarded as statistical significance.

3. Results

3.1. Effects of MV Administration on Physiological and Biochemical Parameters in HFD-Fed Mice. To investigate the therapeutic effects of MV on HFD-induced hepatic steatosis in mice, the changes of physiological and biochemical parameters were determined. As shown in Table 2, administration with high-dose MV significantly reduced the increase in body weight induced by HFD. A similar trend was observed in the change in liver weight. Meanwhile, high-dose MV treatment obviously decreased the levels of serum glucose and insulin in mice fed with HFD. Further, the markedly elevated levels of serum NEFA (p < 0.001), TG (p < 0.05), and T-CHO (p < 0.05) compared with HFD group, which were induced by prolonged feeding with HFD. Furthermore, the markedly elevate levels of serum glucose and insulin in mice fed with HFD were dose-dependently abrogated by MV treatment. Thus, HOMA-IR index, indicating the degree of insulin resistance, was also significantly lowered in the MV groups compared with the HFD group. In addition, MV could restore the serum levels of ALT and AST which are considered as important indicators of liver function and elevated in mice treated with HFD.

3.2. MV Ameliorated HFD-Induced Hepatic Steatosis in Histopathology. To further investigate the effects of MV on fatty liver, we inspected the morphology and pathology of the liver. As exhibited in Figure 1, there were notable changes to the morphological feature of the liver; the liver color of the HFD group displayed pale yellow and that of groups supplemented with different dosages of MV changed from pale yellow to reddish brown. Concordant with the changes of morphology, H&E staining and Oil Red O staining showed that the lipid content of the livers was visibly reduced in the MV groups compared to the HFD-induced severe intrahepatic lipid accumulation from the aspect of the size and the number of lipid droplets. Furthermore, HFD-induced increase of intrahepatic TG
accumulation was significantly inhibited by MV treatment. And quantitative analysis revealed that intrahepatic TG accumulation was dose-dependently reduced after the administration of MV suggesting the significant reduction of hepatic steatosis.

3.3. MV Regulated Lipogenesis, Lipolysis, and Fatty Acid Oxidation in the Liver of HFD-Induced Mice. It is well known that lipid de novo synthesis, lipolysis, and fatty acid oxidation are essential events in the pathogenesis of hepatic steatosis. Therefore, we next measured the levels of protein and mRNA related to lipogenesis, lipolysis, and fatty acid oxidation in the liver. As illustrated in Figures 2(a)–2(c), the expressions of PPAR-γ and SREBP-1 and its downstream protein FASN were increased in NAFLD mice when compared with control group, whereas administration of high-dose MV significantly reduced the expression of these proteins. Concordantly, MV contributed to a dose-dependent decrease of the gene expressions of pparg, srebp1, scd1, and fasn in contrast to those in NAFLD mice (Figure 2(f)). On the other hand, high-dose MV supplementation significantly enhanced the protein expression levels of PPAR-α \( p < 0.05 \) and CPT-1A \( p < 0.05 \) which were reduced by HFD. Similarly, quantitative PCR analysis presented that a reduction in mRNA expression of ppara and cpt1a in the liver tissues of HFD-fed mice was reversed by MV administration. In addition, we also evaluated the mRNA expression levels of lipolysis related genes including atgl and hsl. As shown in Figure 2(g), mice treated with MV exhibited a dose-dependent elevation in the hepatic expression of both atgl and hsl when compared with HFD group. These observations give a hint that MV treatment alleviates hepatic steatosis through the regulation of lipogenesis, lipolysis, and fatty acid oxidation in HFD-induced mice.

3.4. MV Alleviates FFAs-Induced Lipid Accumulation in LO2 Cells. To further explore the effects and mechanisms of MV, LO2 cells were used to establish cell model of hepatic steatosis. As exhibited in Figure 3(b), incubation with 15, 30, and 60 μM MV for 24 hours had no influences on cell viability, while 120 μM MV significantly reduced cell viability. Then we examined the effects of MV upon lipid accumulation in FFAs-treated LO2 cells. As manifested qualitatively by Oil Red O staining and quantitatively by TG measurement, in FFAs-treated LO2 cells, an obvious accumulation of intracellular lipid droplets was observed, which was dose-dependently alleviated by MV treatment (Figures 3(a), 3(c), and 3(d)).

To validate the potential mechanisms of MV on the modulation of lipid metabolism in FFAs-treated LO2 cells, the expression of key proteins to de novo lipogenesis and fatty acid oxidation were analyzed. Consistent with in vivo study, FFAs treatment significantly upregulated the protein expression levels of FASN, SREBP-1, and PPAR-γ, which were dose-dependently suppressed by treatment with different concentrations of MV (Figures 3(e)–3(g)). Meanwhile, FFAs incubation led to decreased protein expression levels of PPAR-α and CPT-1A, which were significantly enhanced by MV incubation. Taken together, these findings

### Table 1: Primer sequences for quantitative PCR.

| Target genes | Forward primer (5′ → 3′) | Reverse primer (5′ → 3′) |
|--------------|--------------------------|--------------------------|
| fasn         | CAGCAGAGTCTACAGCTACCT    | ACCACCAAGAGCCTTATGCG     |
| srebp1       | AAGCAATCACTGAGAGCGTGGG   | AAGGAAAGGGCCTACTCTGGAGG  |
| pparg        | CGAGTTGAGCAAGAACAGTTGA   | CAGGCTGTGTCCTCAGAGG      |
| scd1         | TACACCGCCTTTGCGGATT      | GCCGTGCGCTGTAAATGCTTG    |
| ppara        | AGGGTGGCCTGAGGATGAGGA    | GTTCACCTACGAGTGCCATT     |
| cpt1a        | GACATGGTCTGCTTGCGGCGG    | CAAAGGGTGTAGGTCTGTC      |
| atgl         | AGGACAGCTCCACACACATC     | TGGTTCAGTACGGATTCCCTCT   |
| hsl          | TCACCTGGAGAGCGGAGATA     | CTTGAAATGGCAGCTGACACA    |
| gapdh        | ATGGTGAAGGTCGGTTG       | CATTCTCGGCTTATGCG       |

### Table 2: Physiological and biochemical parameters following 10-week administration of MV in HFD-fed C57BL/6 mice.

| Parameter                  | Control | HFD           | Low-dose MV | Medium-dose MV | High-dose MV |
|---------------------------|---------|---------------|-------------|----------------|--------------|
| Body weight (g)           | 25.27 ± 0.40 | 40.82 ± 1.97*** | 37.24 ± 1.82 | 36.40 ± 2.33 | 33.12 ± 1.97#  |
| Liver weight (g/Kg b.w.)  | 41.69 ± 1.09 | 31.38 ± 0.76*** | 31.40 ± 0.79 | 32.63 ± 0.52 | 34.88 ± 1.12#  |
| NEFA (μmol/L)             | 334.6 ± 13.8  | 500.2 ± 19.4*** | 458.0 ± 21.6  | 408.9 ± 11.4### | 409.0 ± 9.0#### |
| TG (mmol/L)               | 0.79 ± 0.06  | 1.11 ± 0.07*** | 1.09 ± 0.07   | 1.07 ± 0.03   | 0.93 ± 0.05#   |
| Insulin (mIU/L)           | 3.88 ± 0.26  | 6.86 ± 0.32*** | 5.9 ± 0.29    | 5.09 ± 0.31### | 4.11 ± 0.44### |
| HOMA-IR                   | 0.66 ± 0.04  | 1.67 ± 0.14*** | 1.29 ± 0.07#  | 1.06 ± 0.07### | 0.78 ± 0.10#### |
| ALT (U/L)                 | 15.87 ± 1.06 | 22.34 ± 2.79*  | 23.25 ± 1.87  | 20.30 ± 2.73  | 18.76 ± 2.19   |
| Body weight (g)           | 20.41 ± 1.27 | 31.78 ± 3.42*  | 25.67 ± 1.33  | 19.96 ± 2.98  | 18.68 ± 2.08#  |

Data are expressed as the mean ± SEM (n = 9). *p < 0.05 vs. control; **p < 0.01 vs. control; ***p < 0.001 vs. control; #p < 0.05 vs. HFD; ##p < 0.01 vs. HFD; ###p < 0.001 vs. HFD.
imply that MV treatment inhibits de novo lipogenesis and enhances fatty acid oxidation in LO2 cells, thus reducing hepatic steatosis in cell model.

3.5. MV Improved Hepatic Steatosis through AMPK Activation. A considerable body of literature reports that AMP-activated protein kinase (AMPK) plays an important role in hepatocyte fatty acid metabolism including lipogenesis, lipolysis, and fatty acid oxidation [14, 15]. To determine the role of AMPK in MV treatment on hepatic steatosis, AMPK phosphorylation level was examined in liver tissues and LO2 cells. As demonstrated in Figure 4(a), compared with control group, AMPK phosphorylation level of HFD group was considerably decreased, which was dose-dependently upregulated by MV administration. Similar results were observed in LO2 cells incubated with different concentrations of MV (Figure 4(b)), implying that AMPK activation is involved in the therapeutic effects of MV on hepatic steatosis.

To verify whether MV ameliorates FFAs-induced steatosis via AMPK-dependent pathway, Compound C, an AMPK inhibitor, was adopted to treat LO2 cells. Intriguingly, Oil Red O staining exhibited that 60 μM MV treatment
FASN/tubulin (ratio)

Control
HFD
Low-dose MV
Medium-dose MV
High-dose MV

**
###

SREBP-1/tubulin (ratio)

Control
HFD
Low-dose MV
Medium-dose MV
High-dose MV

*
#

PPAR-γ/tubulin (ratio)

Control
HFD
Low-dose MV
Medium-dose MV
High-dose MV

*
##

PPAR-α/tubulin (ratio)

Control
HFD
Low-dose MV
Medium-dose MV
High-dose MV

*
#

CPT-1A/tubulin (ratio)

Control
HFD
Low-dose MV
Medium-dose MV
High-dose MV

*
#

Relative mRNA expression

fasn  pparg  scd 1  srebp 1

***
#
#

(f)

Figure 2: Continued.
**Figure 2:** MV improved hepatic steatosis through inhibiting lipogenesis and promoting fatty acid oxidation and lipolysis in HFD-fed C57BL/6 mice. Representative immunoblot detection of FASN (a), SREBP-1 (b), PPAR-γ (c), PPAR-α (d), and CPT-1A (e) protein expression. (f) The mRNA expression of lipogenesis-relative genes including *fasn*, *srebp1*, *pparg*, and *scd1*. (g) The mRNA expressions of ppara, cpt1a, hsl, and atgl in the liver tissues of HFD-fed mice. Data are presented as mean ± SEM (n = 3-4). *p < 0.05 vs. control; **p < 0.01 vs. control; ***p < 0.001 vs. control; #p < 0.05 vs. HFD; ##p < 0.01 vs. HFD.

**Figure 3:** Continued.
significantly reduced the size and number of lipid droplets in FFAs-incubated cells, which was markedly abrogated by 5 μM Compound C (Figure 4(c)). These results indicate that MV improved hepatic steatosis in an AMPK-dependent manner.

4. Discussion

Positive energy balance between excessive energy intake and less energy expenditure results in the increased incidence of overweight and obesity which is tightly associated with incidence of NAFLD. There is strong evidence that for each one unit increase in body mass index, the morbidity of NAFLD enhances by 13% to 38% [16]. High levels of plasma FFAs are primarily originated from dietary fatty acids and adipose tissue lipolysis, which is vital to the pathological process of hepatic steatosis [17, 18]. Ectopic accumulation of hepatic lipids could attribute to boosted uptake of FFAs, strengthened de novo lipogenesis, decreased fatty acid oxidation, and suppressed very low-density lipoproteins export in hepatocytes [19], all alterations unpinning the occurrence of NAFLD. Therefore, the rationale for inhibition of de novo lipogenesis and enhancement of lipolysis and fatty acid oxidation could be therapeutic strategies for treating NAFLD. The mimic rodent model of hepatic steatosis can be induced by dietary including methionine and choline deficiency diet, HFD, cholesterol mingled cholate diet, and fructose diet. Among a series of the aforementioned rodent model, HFD-based animal model has been widely used for studies because of its similarity to human NAFLD in terms of the pathogenesis and alteration of metabolic parameters, especially the excess influx of FFAs into the liver causing lipotoxic process and promoting a hepatic proinflammatory state [20]. Therefore, in our study, hepatic steatosis was induced in HFD-treated mice to investigate the beneficial effects of MV upon hepatic steatosis including impaired de novo lipogenesis, lipolysis, and fatty acid oxidation.

The present study demonstrated that MV improved physiological, biochemical, and pathohistological changes, key characteristics of NAFLD, including weight gain,
elevated NEFA, and hepatic steatosis, together with insulin resistance, which is coincident with the previous report that the major contributing factors to the pathogenesis of hepatic steatosis are insulin resistance and increased influx of free fatty acids in the liver [4]. In order to deeply understand the molecular mechanisms involved in the pathogenesis of NAFLD and therapeutic effect of MV, western blotting and quantitative PCR have been done to investigate the expression of key protein and genes related to lipogenesis, lipolysis, and fatty acid oxidation. Fatty acid synthase
(FASN) and stearoyl-CoA desaturase-1 (SCD1) are lipogenic proteins required for de novo lipogenesis and encoded by the 
fasn and scd1 gene, respectively, which are preferentially 
regulated by a transcriptional factor, SREBP-1. PPAR-γ is 
another transcriptional factor participating in the regulation 
of triacylglycerol synthesis in the liver, whereas PPAR-α 
regulates CPT-1A, which is responsible for the mitochondrial 
transport and oxidation of fatty acids. ATGL and HSL 
could contribute to the activity of liver lipolysis under 
physiological conditions. The results show that the increased 
expression of pparγ, srebp1, scd1, and fasn and the 
suppressed expression of atgl, hsl, ppara, and cpt1a in the liver in 
HFD-fed mice were reversed by MV treatment. Results from 
FFAs-treated LO2 cells further indicating that MV ameliorated 
hepatic lipid accumulation through decreasing de novo 
lipogenesis, increasing lipolysis and fatty acid oxidation, 
which is consistent with previous knowledge that increased 
TG production and reduced fatty acid oxidation play 
important roles in NAFLD pathogenesis [21].

Furthermore, MV exerted a dose-dependent effect of 
increasing the AMPK phosphorylation, and the reduction of 
the size and number of lipid droplets in FFAs-incubated cells 
by MV was markedly abrogated by Compound C indicating 
that MV could improve hepatic lipid accumulation through 
activation of AMPK signaling pathway. AMPK acts as an 
important regulator of multiple metabolic pathways including 
hepatic lipid metabolism and its activation is considered 
as a potentially adversarial approach for the 
prevention and treatment of NAFLD [14, 22]. AMPK 
consists of α, β, and γ subunits. The threonine 172 is the 
major trigger point on AMPKα, which plays an important 
role in the process of AMPK activation [23]. Activation of 
AMPK regulates hepatic lipid metabolism through modu-
lating several transcriptional factors, including SREBP-1, as 
well as PPAR-α and PPAR-γ [24, 25]. These transcriptional 
factors regulate genes responsible for de novo lipogenesis 
and fatty acid oxidation, which are two crucial events to 
adapt to fat accretion in the liver and to the development of 
NAFLD. In an individual with NAFLD, the level of de novo 
ilipogenesis increased more than 3-fold compared with the 
normal individual [26].

5. Conclusions
In conclusion, MV ameliorates HFD-induced hepatic 
steatosis through AMPK activation which regulates SREBP-
1, PPAR-γ, and PPAR-α and thus improves the imbalance 
between lipid acquisition and lipid removal (Figure 5), 
providing us with a potential lead compound for developing 
new drug. However, the deeper understanding of the 
mechanism of therapeutic effect of MV upon NAFLD and its 
druggability need to be elucidated.

Data Availability
The data used to support the findings of this study are in-
cluded within the article.

Conflicts of Interest
The authors declare no conflicts of interest.

Authors’ Contributions
Linghuan Li did all the experiments. Linghuan Li and 
Hanbing Li wrote the paper. Jiameng Qi, Can Wang, and 
Wanfang Zheng contributed with the collection and analysis 
of tissue samples. Linghuan Li and Hanbing Li designed the 
research plan and supervised the study. Hanbing Li has

![Figure 5: Summary of effects of mogroside V upon hepatic steatosis in mice fed an HFD.](image-url)
primary responsibility for the final content. All authors have read and agreed to the published version of the manuscript.

Acknowledgments
This research was supported by the Natural Science Foundation of Zhejiang Province (LY18H070004 and LY14H310003).

Supplementary Materials
Figure S1: HPLC of mogroside V. Table S1: the ingredients of high-fat diet and standard chow diet. (Supplementary Materials)

References
[1] A. M. Diehl and C. Day, "Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis," New England Journal of Medicine, vol. 377, no. 21, pp. 2063–2072, 2017.
[2] Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes," Hepatology, vol. 64, no. 1, pp. 73–84, 2016.
[3] M. C. Hernández-Rodas, R. Valenzuela, F. Echeverría et al., "Supplementation with docosahexaenoic acid and extra virgin olive oil prevents liver steatosis induced by a high-fat diet in mice through PPAR-α and Nrf2 upregulation with concomitant SREBP-1c and NF-kB downregulation," Molecular Nutrition & Food Research, vol. 61, no. 12, 2017.
[4] V. Manne, P. Handa, and K. V. Kowdley, "Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis," Clinics in Liver Disease, vol. 22, no. 1, pp. 23–37, 2018.
[5] R. Valenzuela and L. A. Videla, "The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity," Food & Function, vol. 2, no. 11, pp. 644–648, 2011.
[6] L. Tao, J. Yang, F. Cao et al., "Mogroside IIIIE, a novel antifibrotic compound, reduces pulmonary fibrosis through toll-like receptor 4 pathways," Journal of Pharmacology and Experimental Therapeutics, vol. 361, no. 2, pp. 268–279, 2017.
[7] X.-Y. Qi, W.-J. Chen, L.-Q. Zhang, and B.-J. Xie, "Mogrosides extract from Siraitia grosvenorii scavenges free radicals in vitro and lowers oxidative stress, serum glucose, and lipid levels in allxao-induced diabetic mice," Nutrition Research, vol. 28, no. 4, pp. 278–284, 2008.
[8] J. L. Song, B. Qian, C. Pan et al., "Protective activity of mogroside v against ovalbumin-induced experimental allergic asthma in kunming mice," Journal of Food Biochemistry, vol. 43, Article ID e12973, 2019.
[9] M. Takasaki, T. Konoshima, Y. Murata et al., "Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenorii," Cancer Letters, vol. 198, no. 1, pp. 37–42, 2003.
[10] Y. Zhou, Y. Zheng, J. Ebersole, and C. F. Huang, "Insulin secretion stimulating effects of mogroside v and fruit extract of luo han kuo (Siraitia grosvenorii swingle) fruit extract," Acta Pharmacutica Sinica, vol. 44, pp. 1252–1257, 2009.
[11] H. Liu, X. Qi, K. Yu et al., "AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice," Food & Function, vol. 10, no. 1, pp. 151–162, 2019.
[12] X. Zhang, Y. Song, Y. Ding et al., "Effects of mogrosides on high-fat-diet-induced obesity and nonalcoholic fatty liver disease in mice," Molecules, vol. 23, no. 8, 2018.
[13] Y. Yao, X. Zhao, J. Xin, Y. Wu, and H. Li, "Coumarins improved type 2 diabetes induced by high-fat diet and streptozotocin in mice via antioxidation," Canadian Journal of Physiology and Pharmacology, vol. 96, no. 8, pp. 765–771, 2018.
[14] E. A. Day, R. J. Ford, and G. R. Steinberg, "AMPK as a therapeutic target for treating metabolic diseases," Trends in Endocrinology & Metabolism, vol. 28, no. 8, pp. 545–560, 2017.
[15] B. K. Smith, K. Marcinko, E. M. Desjardins, J. S. Lally, R. J. Ford, and G. R. Steinberg, "Treatment of nonalcoholic fatty liver disease: role of AMPK," American Journal of Physiology-Endocrinology and Metabolism, vol. 311, no. 4, pp. e730–e740, 2016.
[16] L. Pimpin, H. Cortez-Pinto, F. Negro et al., "Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies," Journal of Hepatology, vol. 69, no. 3, pp. 718–735, 2018.
[17] K. Cusi, "Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis," Clinics in Liver Disease, vol. 13, no. 4, pp. 545–563, 2009.
[18] G. Musso, R. Gambino, and M. Cassader, "Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)," Progress in Lipid Research, vol. 48, no. 1, pp. 1–26, 2009.
[19] N. Gruben, R. Shiri-Sverdlov, D. P. Y. Koonen, and M. H. Hofker, "Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?" Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1842, no. 11, pp. 2329–2343, 2014.
[20] S. A. Soto-Alarcón, M. Ortiz, P. Orellana et al., "Docosahexaenoic acid and hydroxytyrosol co-administration fully prevents liver steatosis and related parameters in mice subjected to high-fat diet: a molecular approach," Biofactors, vol. 45, no. 6, pp. 930–943, 2019.
[21] S.-H. Koo, "Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis," Clinical and Molecular Hepatology, vol. 19, no. 3, pp. 210–215, 2013.
[22] D. Garcia, K. Hellberg, A. Chaix et al., "Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD," Cell Reports, vol. 26, no. 1, pp. 192–208, 2019.
[23] S. A. Hawley, M. Davison, A. Woods et al., "Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase," Journal of Biological Chemistry, vol. 271, no. 44, pp. 27879–27887, 1996.
[24] G. Serviddio, F. Bellanti, and G. Vendemiale, "Free radical biology for medicine: learning from nonalcoholic fatty liver disease," Free Radical Biology and Medicine, vol. 65, pp. 952–968, 2013.
[25] F. Echeverria, R. Valenzuela, A. Bustamante et al., "High-fat diet induces mouse liver steatosis with a concomitant decline in energy metabolism: attenuation by eicosapentaenoic acid (EPA) or hydroxytyrosol (HT) supplementation and the additive effects upon EPA and HT co-administration," Food & Function, vol. 10, no. 9, pp. 6170–6183, 2019.
[26] J. E. Lambert, M. A. Ramos–Roman, J. D. Browning, and E. J. Parks, "Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease," Gastroenterology, vol. 146, no. 3, pp. 726–735, 2014.